[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"refractory-chronic-cough\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:refractory-chronic-cough":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,40,69,103,124,159,188,231],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100644548","phase-2-the-effect-of-nalbuphine-extended-release-nal-er-on-cough-in-participants-with-refractory-chronic-cough-rcc-100644548",false,"NCT07671924","The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)","A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Participants With Refractory Chronic Cough","LAKE","Inclusion Criteria:\n\n* Meets society guideline-based criteria for a diagnosis of RCC defined as:\n\n  * Insufficient improvement in cough after treatment for any identified cough-associated conditions.\n  * Unexplained cough for which an underlying condition has not been determined despite adequate investigation with diagnostic tests and trials of therapy.\n* Persistent and chronic cough for at least one year prior to Screening.\n* Chest computed tomography (CT) or chest radiograph of the thorax performed within the last 24 months and after the onset of chronic cough OR the procedure completed by the Investigator during the Screening period, that does not show any abnormality considered to be significantly contributing to the RCC in the opinion of the Principal Investigator.\n* 24-hour objective cough frequency ≥10 coughs\u002Fhour based on VitaloJAK® cough monitor recording performed during the Screening and Placebo Run-in Periods as well as a minimum recording duration of 20 hours suitable for analysis during the placebo Run-in assessment.\n* Forced expiratory volume in 1 second (FEV1) \u002Fforced vital capacity (FVC) ratio ≥ 60% as determined by spirometry adhering to American Thoracic Society (ATS)\u002FEuropean Respiratory Society (ERS) guidelines.\n\nExclusion Criteria:\n\n* Clinical diagnosis of sleep apnea and\u002For use of continuous positive airway pressure (CPAP).\n* Upper or lower respiratory tract infection or change in pulmonary status in the 4 weeks prior to the Screening visit or during the Screening or PBO Run-in periods.\n* History of bronchiectasis, chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF), or other significant respiratory disorder that might affect cough.\n* History of uncontrolled asthma defined as one of the following:\n\n  * ≥1 clinically significant exacerbation in the last 6 months, OR\n  * ≥2 clinically significant exacerbations in the past 12 months (a clinically significant asthma exacerbation is defined as requiring the use of systemic corticosteroids).\n* Current smoker or vaper or current use of tobacco smoke, cannabis smoke, or nicotine vaper.\n* Individuals who have stopped smoking or vaping within the past 6 months, or those with \\>20 pack-year smoking history.\n* Current active tuberculosis or nontuberculous mycobacterial infection, a history of latent untreated tuberculosis, or a history of incompletely treated tuberculosis.\n* Speech therapy\u002Fphysiotherapy for RCC starting within 4 weeks of Baseline or during the study. Speech therapy\u002Fphysiotherapy is acceptable if the participant has started the therapy more than 4 weeks prior to the Baseline visit AND plans to continue the therapy through the Titration and Fixed-dose Treatment Period.\n* Known intolerance \\[gastrointestinal, central nervous system (CNS) symptoms\\], hypersensitivity, or drug allergy considered to be related to an opioid drug or known hypersensitivity to nalbuphine or to NAL ER excipients.\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to evaluate the efficacy and safety of Nalbuphine ER Extended-release tablets for the treatment of participants with RCC.",[27],"Refractory Chronic Cough","NOT_YET_RECRUITING","2026-06-22",{"date":31,"type":32},"2026-06-26","ACTUAL",{"date":34,"type":21},"2026-06",{"date":36,"type":21},"2027-09",{"name":38,"class":39},"Trevi Therapeutics","INDUSTRY",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100641795","phase-3-a-24-week-study-of-the-efficacy-and-safety-of-blu-5937-in-adults-with-refractory-chronic-cough---china-extension-100641795","NCT07650084","A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension","A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2) - China Extension","CALM-2","Inclusion Criteria:\n\n* Capable of giving signed informed consent\n* Refractory chronic cough (including unexplained chronic cough) for at least one year\n\n  * Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose\n\nExclusion Criteria:\n\n* Current smoker\u002Fvaper (all forms of smoking and inhaled substances, including, cannabis\u002Ftobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \\>20 pack-year smoking history\n* Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway\u002Frespiratory disorder that might affect cough based on clinician assessment\n* Respiratory tract infection within 4 weeks before screening\n* Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening\n* History of malignancy in the last 5 years\n* History of alcohol or drug abuse within the last 3 years\n* Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus.\n* Previous participation in a BLU-5937 trial","80 Years",{"count":50,"type":21},75,[52],"PHASE3","This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).",[27],[56,57],"Cough","Chronic Cough","RECRUITING","2026-06-10",{"date":61,"type":32},"2026-06-16",{"date":63,"type":32},"2025-11-21",{"date":65,"type":21},"2028-06-02",{"name":67,"class":39},"GlaxoSmithKline",38,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100589926","phase-2-mechanisms-of-change-in-behavioral-cough-suppression-therapy-for-refractory-chronic-cough-100589926","NCT06960759","Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough","CoughLESS","INCLUSION CRITERIA\n\nTo be eligible to participate, participants must meet the following criteria:\n\n* 18 - 99 years of age\n* Diagnosis of refractory or unexplained chronic cough\n* Normal chest imaging (x-ray or CT scan) within past 2 years, without change in cough symptoms\n* If you a potential participant has asthma, the following criteria must be met:\n\n  * Asthma diagnosed by a pulmonary provider\n  * Documentation from a pulmonary provider that asthma is well-controlled\n  * Agree to carry prescribed rescue inhaler to each study visit\n  * Can tolerate, and agree to, avoid rescue inhaler use for 4 hours prior to each study visit. If rescue inhaler use is unavoidable within 4 hours of a study visit, agree to inform researchers in advance so that the session can be rescheduled.\n* Normal pulmonary function testing with spirometry (FEV1\u002FFVC of at least 70% if diagnosed with asthma) within 2 years (6 months for those with a diagnosis of asthma), without change in symptoms since (NOTE: spirometry is included as part of cough threshold testing and can serve as this criteria if the participant has not had spirometry within the designated time.)\n* Laryngoscopy or stroboscopy within 2 years without evidence of structural pathology and no change in vocal quality since exam\n* Proficient reader\u002Fspeaker of English\n* Willing to take a pregnancy test before enrollment (if applicable)\n* Willing to use contraception during the study (if applicable)\n* Access to reliable internet, working email address (for surveys) and a smart phone (for use with CoughMonitor Watch)\n* Demonstrates understanding in study procedures and risks in order to consent\n* Available, and willing, to comply to all study procedures and clinic visits.\n\nEXCLUSION CRITERIA\n\nAny of the following will be grounds for exclusion from the study:\n\n* Currently a smoker of any substance or has a positive history of smoking any substance within the last 6 months\n* Currently suffering from any signs of an upper respiratory infection (other than cough)\n* Hemoptysis (coughing up blood) within the last 6 months\n* Pulmonary diagnosis other than asthma\n* Asthma criteria - participant is deemed ineligible if screened for one or more of the following:\n\n  * Use of rescue inhaler in response to active asthma symptoms ≥ 2 times per week\n  * Respiratory related emergency department visit within the past 4 weeks\n  * Respiratory related ICU admission within the past 12 months\n  * Asthma exacerbation requiring systemic corticosteroid use within the past 4 weeks\n* Pregnant or trying to become pregnant\n* Any complaints or clinical symptoms of dysphagia\n* Live with someone with chronic cough or work with someone with chronic cough who is in close proximity (e.g., within 25 feet) on a daily or nearly daily basis\n* Known allergy to peppers\n* Currently receiving or has received BCS therapy for management of refractory chronic cough\n* Excluded concomitant medications:\n\n  * Inhaled pulmonary medications (inhaled corticosteroids, short-acting beta agonists, long-acting beta-agonist, short-acting muscarinic antagonists), unless prescribed for asthma by pulmonary provider: 30 days prior to Visit 1 through completion of study participation\n  * ACE inhibitor (benazepril, captopril, enalapril, fosiniopril, lisinopril, perindopril, quinapril, ramipril, trandolapril): 30 days prior to Visit 1 through completion of study participation.\n  * Narcotic antitussive (hydrocodone, oxycodone, morphine, codeine, tramadol): 7 days prior to Visit 1 through completion of study participation\n  * Non-narcotic antitussive (benzonatate\u002FTessalon, dextromethorphan\u002FDelsym, carbetapentane\u002FSolotuss): 7 days prior to Visit 1 through completion of study\n  * P2X3 receptor antagonist (gefapixant\u002FLyfnua): 14 days prior to Visit 1 through completion of study\n  * Any off-label prescription medication prescribed for cough (pregabalin\u002FLyrica, gabapentin\u002FNeurontin, amitriptyline\u002FElavil): 14 days prior to Visit 1 through completion of study \\*if a neuromodulator is prescribed for something other than cough, participant must be on a stable dose for a minimum of 7 days\n\nThe following additional exclusion criteria will apply to participants who will undergo fMRI:\n\n* Presence of metal implants, devices or fragments (e.g., shrapnel) in the body\n* Claustrophobia","99 Years",{"count":78,"type":21},135,[24],"This study is testing new ways to help people who have chronic cough that has not improved with typical treatments. One approach is called behavioral cough suppression (BCS) therapy, which teaches people techniques to stop themselves from coughing. Another approach uses a natural substance thought to help reduce the body's sensitivity to cough triggers.\n\nIn this study, we will test two treatments and include one no-treatment control group. The control group will undergo baseline testing, cough monitoring, and an fMRI brain scan and will be offered BCS at end of study participation.\n\nThe two treatments include:\n\n* BCS therapy with active inhaled treatment (BCS+active),\n* BCS therapy with inactive inhaled treatment (BCS+inactive),\n\nThe investigators will enroll 135 adults with refractory chronic cough (RCC). 100 participants who qualify and are willing and able to complete 14 study visits in the clinic and two online study visits will be randomly assigned to one of the two treatments. The no-treatment control group (n=35) will be recruited from adults with RCC who are willing to complete baseline testing and fMRI but are not able or willing to attend 14 study clinic visits. These participants will not be randomized.\n\nThe investigators want to find out how these treatments affect:\n\n* How sensitive someone is to things that make them cough,\n* How well they can hold back a cough when they try,\n* How their brain responds to things that cause an urge-to-cough,\n* And how much their coughing affects their quality of life.\n\nThe investigators believe both treatments will reduce sensitivity to cough stimulants, reduce cough severity, and improve quality of life, but BCS+active inhaled treatment will work better than BCS+inactive inhaled treatment.",[82,27,83],"Chronic Cough (CC)","Unexplained Chronic Cough",[85,86,87,88,89,90,91],"cough hypersensitivity syndrome","randomized control trial","neurogenic cough","refractory chronic cough","unexplained chronic cough","chronic cough","behavioral cough suppression therapy","2026-06-01",{"date":94,"type":32},"2026-06-03",{"date":96,"type":21},"2026-06-29",{"date":98,"type":21},"2030-03-31",{"name":100,"class":101},"University of Montana","OTHER",3,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100630116","phase-2-a-phase-2-study-of-hw091077-in-participants-with-refractory-chronic-cough-or-unexplained-chronic-cough-rccucc-100630116","NCT07483489","A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC\u002FUCC).","A Randomized，Double-Blind, Multicenter，Placebo-Controlled, Parallel-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of HW091077 in Participants With Refractory Chronic Cough or Unexplained Chronic Cough (RCC\u002FUCC).","Inclusion Criteria:\n\n* Aged between 18 and 80 years;\n* Diagnosed with refractory chronic cough or unexplained chronic cough, with a cough lasting for ≥1 year;\n* Chest CT at screening shows no abnormalities that the investigator believes may lead to chronic cough;\n* Cough severity VAS score ≥40 mm ;\n* Female participants of childbearing potential must have a negative pregnancy test and must not be breastfeeding; male and female participants must have no plans for pregnancy during the entire clinical trial and within 6 months after the last dose, and agree to use medically accepted reliable contraceptive methods during the trial and within 6 months after the last dose;\n* Fully understand the study, voluntarily sign the informed consent form, and be able to comply with the study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n* Currently smoking, or having quit smoking within 12 months prior to screening;\n* A smoking history of \\>20 pack-years;\n* Ongoing exposure to inhaled toxic substances within 12 months prior to screening or currently;\n* A history of drug abuse or alcoholism (weekly alcohol consumption of 14 units of alcohol: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);\n* Diagnosed with chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, bronchial asthma (except for cough variant asthma), or other airway\u002Frespiratory diseases that may affect coughing;\n* Respiratory tract infection or significant changes in lung status within 4 weeks prior to screening;\n* FEV1\u002FFVC)\\\u003C60%;\n* Clinically significant electrocardiogram abnormalities, such as QTc interval ≥450 ms, long QT syndrome, etc.;\n* Use of angiotensin-converting enzyme inhibitors (ACEIs) within 3 months prior to screening;\n* Plans to initiate new treatment for RCC\u002FUCC during the trial period;\n* Taste disturbance within 1 month prior to screening;\n* Use of any P2X3 receptor antagonist within 1 year prior to screening;",{"count":111,"type":21},180,[24],"This is a randomized, multicenter, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HW091077 in Chinese adult subjects with refractory chronic cough or unexplained chronic cough (RCC\u002FUCC).",[27],"2026-03-16",{"date":117,"type":32},"2026-03-19",{"date":119,"type":21},"2026-05-01",{"date":121,"type":21},"2028-08-30",{"name":123,"class":39},"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100447723","phase-2-efficacy-of-two-doses-of-duloxetine-and-amitriptyline-in-subjects-with-refractory-chronic-cough-100447723","NCT05110144","Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough","A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating the Efficacy of Two Doses of Duloxetine & Amitriptyline in Subjects With Refractory Chronic Cough","MACS-1","Inclusion Criteria\n\n* Chest radiograph or computed tomography (CT) of the thorax within the last 1 year not demonstrating any abnormality considered to be significantly contributing to the refractory chronic cough in the opinion of the Principal Investigator\n* Have a diagnosis of refractory chronic cough or unexplained cough for at least one year according to the American College of Chest Physicians guidelines\n* Have a score of ≥ 40mm on the Cough Severity VAS at Screening.\n* Women of child-bearing potential must agree to use 2 forms of acceptable birth control and make no donation of eggs from Screening through the end of the 8-week study period. Acceptable birth control methods include established use of oral, injected, or implanted hormonal methods of contraception; intrauterine device (IUD) or intrauterine system (IUS); tubal ligation; or male sterilization. Double-barrier method (diaphragm for female subject and condom for male partner with spermicidal) satisfies the requirement for 2 forms of acceptable birth control. When concordant with the preferred lifestyle of the subject, true and complete abstinence (not periodic abstinence) is acceptable.\n* Male subjects and their partners of child-bearing potential must use 2 methods of acceptable birth control, 1 of which must be a barrier method, and make no donation of sperm from Screening until 3 months after the last dose of study drug at the end of 8 weeks.\n* Have provided written informed consent.\n* Are willing and able to comply with all aspects of the protocol.\n\nExclusion Criteria\n\n* Current smoker (cigarettes, e-cigarettes or marijuana) or former smokers who have smoked within the past 12 months.\n* Former smokers with \\> 20 pack-year history of smoking\n* Ongoing treatment with an ACE-inhibitor that is considered as the potential cause of a subject's cough or requiring treatment with an ACE-inhibitor during the study or within 12 weeks prior to the Screening\u002FBaseline Visit (Day -14 to Day 0).\n* FEV1\u002FFVC \\\u003C 60%.\n* History of upper or lower respiratory tract infection or recent significant change in pulmonary status within 4 weeks of the Screening\u002FBaseline Visit (Day -14 to Day 0)\n* History of opioid use specifically prescribed for chronic cough within 2 weeks of the Screening\u002FBaseline Visit (Day -14 to Day 0). Use of opioids for other indications (for example, to treat pain) is permitted.\n* History of baclofen use specifically prescribed for chronic cough within 2 weeks of the Screening\u002FBaseline Visit (Day -14 to Day 0). Use of baclofen for other indications (for example, to treat spasticity) is permitted.\n* Diagnosis of COPD, bronchiectasis, interstitial lung disease or cystic fibrosis\n* Presence of an untreated or undertreated cause for the patient's chronic cough (as determined by the treating\u002Freferring physician per ACCP guidelines). e.g. uncontrolled asthma, GERD or post-nasal drainage that could potentially explain the patient's chronic cough.\n* Requiring concomitant therapy with prohibited medications (outlined below)\n* Treatment with any pharmaceutical or biological investigational therapy (excluding coronavirus disease of 2019 (COVID) vaccination and COVID related monoclonal antibody therapy)\n* Participation in another clinical trial that does not allow co-enrollment within 4 weeks prior to the Screening\u002FBaseline Visit (Day -14 to Day 0)\n* Total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3x the upper limit of normal (ULN) during screening.\n* Serum creatinine \\\u003C 30 mL\u002Fmin, hemodialysis or peritoneal dialysis\n* Advanced liver disease as defined by the presence of cirrhosis and\u002For signs of portal hypertension\n* History of previous hypersensitivity or intolerance to Duloxetine \\& Amitriptyline (patients who have previously been on either amitriptyline or duloxetine for chronic cough or other reasons and have tolerated the medication will be offered participation regardless of previous response to therapy).\n* Currently pregnant or breastfeeding female subject.\n* Presence of any medical condition or disability that the investigators believe could interfere with the assessment of safety or efficacy in this trial or compromise the safety of the subject.\n* Planned or anticipated major surgical procedure or other activity that would interfere with the subject's ability to comply with protocol-mandated assessments (e.g., extended travel) during the subject's participation in the study.\n* Currently taking either another SSRI, SNRI or MAO inhibitor which the patient cannot safely discontinue at least 2 weeks prior to the screening period.\n* The following therapies are prohibited from 2 week prior to the Screening\u002FBaseline Visit (Day -14 to Day 0) through the end of the 8-week blinded treatment period.\n\n  * Opioids (of any kind including tramadol \\& codeine) specifically prescribed for treatment of cough\n  * Dextromethorphan\n  * Guaifenesin\n  * Chlorpheniramine\n  * Benzonatate\n  * Trazodone\n  * Pregabalin or gabapentin prescribed for chronic cough\n  * 1% tetracaine lollipops prescribed for chronic cough\n  * 4% nebulized lidocaine solution prescribed for chronic cough\n  * Any SSRI (selective serotonin reuptake inhibitor) e.g. bupropion, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine.\n  * Any SNRI (serotonin-norepinephrine reuptake inhibitor) e.g. venlafaxine, desvenlafaxine, milnacipran, levomilnacipran\n  * Any Tricyclic antidepressant e.g. doxepin, clomipramine, nortriptyline, imipramine, protriptyline, amoxapine, trimipramine\n  * Any MAO (Monoamine oxidase) inhibitor. e.g. phenelzine, selegiline, isocarboxacid or tranylcypromine\n  * Patients who were previously prescribed either amitriptyline or duloxetine for chronic cough will be eligible for the study as long as they had discontinued the medication at least 12 weeks prior to the Screening\u002FBaseline Visit (Day -14 to Day 0).\n* The following therapies are prohibited from 4 week prior to the Screening\u002FBaseline Visit (Day -14 to Day 0) through the end of the 8-week blinded treatment period.\n\n  • Investigational biologic or pharmaceutical therapies (excluding COVID vaccination and COVID related monoclonal antibody therapy)\n* The following therapies are prohibited from 12 week prior to the Screening\u002FBaseline Visit (Day -14 to Day 0) through the end of the 8-week blinded treatment period.\n\n  * Treatment with an ACE-inhibitor","75 Years",{"count":134,"type":21},50,[24],"This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with refractory chronic cough (RCC)",[27],[56,139,140,141,142,143,144,145,87,146,147,148],"Chronic cough","asthma","GERD","Upper airway cough syndrome","antitussives","cough hypersensitivity","refractory cough","Gastroesophageal reflux","Chronic rhinosinusitis","refractory","2026-01-19",{"date":151,"type":32},"2026-01-21",{"date":153,"type":32},"2021-11-01",{"date":155,"type":21},"2026-12",{"name":157,"class":101},"Mayo Clinic",1,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100615124","phase-4-a-2x2-factorial-randomized-open-label-trial-to-evaluate-neuromodulators-and-cough-control-therapy-in-patients-with-refractory-or-unexplained-chronic-cough-100615124","NCT07288528","A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough","A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough (FORTITUDE)","FORTITUDE","Inclusion Criteria:\n\n1. Adults (≥18 years old) with either:\n2. Refractory chronic cough (RCC), defined as having one or more identifiable causes of cough (asthma, allergic rhinitis, and\u002For GERD), but with previous trials of treatment targeting the underlying condition leading to no cough resolution; OR\n3. Unexplained chronic cough (UCC), defined as having a cough lasting \\>8 weeks with (i) a normal chest X-ray\u002FCT in the last 5 years and since the onset of chronic cough; (ii) FEV1 and FVC ≥80% predicted or \\>lower limit of normal (LLN); (iii) FEV1\u002FFVC ≥0.7 or \\>LLN; (iv) no evidence of asthma; and (vi) no regular symptoms of nasal\u002Freflux disease.\n\nExclusion Criteria:\n\n1. Those who, in the opinion of the investigator, have previously tried low-dose morphine, pregabalin, and\u002For CCT with full intervention fidelity for the treatment of RCC\u002FUCC;\n2. Are currently taking morphine or pregabalin for the treatment of any indication (i.e., RCC\u002FUCC or chronic pain);\\*\n3. Are currently taking other centrally-acting medication (i.e., gabapentin, amitriptyline, dextromethorphan) for the treatment of any indication (i.e., RCC\u002FUCC, seizures, or depression);\\*\n4. Have a history of opioid or substance abuse that, in the opinion of the investigator, may interfere with the conduct of the study;\n5. Are a current smoker, or ex-smoker with a \\>20 pack-year history who have abstained from smoking for \\\u003C6 months;\n6. Have cough due to angiotensin-converting enzyme inhibitor use;\n7. Have symptoms of an upper respiratory infection within the last month that have not resolved;\n8. Had an asthma exacerbation within the last month that requires an increase or start of an oral corticosteroid;\n9. Have other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, interstitial lung disease, or severe bronchiectasis;\n10. Have language, memory, cognitive, or psychiatric issues that may prevent optimal participation;\n11. Have creatinine clearance \\\u003C15 mL\u002Fmin, including individuals with end-stage renal disease who require hemodialysis or peritoneal dialysis;\n12. Have any other condition that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant;\n13. Have participated in another clinical trial of an investigational medicinal product within 30 days;\n14. Pregnant or breastfeeding; or\n15. Females of child-bearing potential who:\n\n    1. Do not agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of 3 months.\n    2. Acceptable methods of birth control include oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant, double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening.\n    3. Females who are not of child-bearing potential will be defined as females who have undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening.\n\n       * Participants taking any of the above medications at baseline will only be eligible if they are willing and medically able to safely discontinue them at least 2 weeks prior to the first study visit. Eligibility will be confirmed by the local study investigator prior to enrolment.",{"count":168,"type":21},124,[170],"PHASE4","The FORTITUDE trial will provide head-to-head evidence on the benefits and harms of two commonly prescribed neuromodulators (low-dose morphine and pregabalin), the effectiveness of a virtual cough control therapy, exploratory assessment of potential synergy in combining these interventions, and the long-term outcomes of these treatments in patients with refractory or unexplained chronic cough.",[56,27,83,173,57],"Cough Hypersensitivity Syndrome",[56,57,175,176,177,27,83],"Morphine","Pregabalin","Non-Pharmacologic Therapy","2025-12-04",{"date":180,"type":32},"2025-12-17",{"date":182,"type":21},"2026-04-01",{"date":184,"type":21},"2029-07-01",{"name":186,"class":101},"McMaster University",5,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":195,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":158},"100598392","cough-management-wellness-app-for-refractory-or-unexplained-chronic-cough-100598392","NCT07070895","Cough Management Wellness App for Refractory or Unexplained Chronic Cough","A Prospective Decentralized Investigation of the Effect of a Cough Management Feature Inside a Wellness Application (CoughPro) in Refractory or Unexplained Chronic Cough (RCC\u002FUCC)","Inclusion Criteria:\n\n* Age 21 or older.\n* Currently suffering from a cough that started at least 8 weeks ago that is largely unproductive (i.e., at least 50% of the time the cough produces zero mucus that needs to be spit out or swallowed).\n* Normal chest X-ray or chest CT scan at some point that was prescribed specifically for their cough.\n* At least one physician visit for cough with standard-of-care therapy but inadequate symptom relief.\n* Stability of treatment: willing to avoid new cough treatments during study or report changes if they occur.\n* Ability to comply: willing\u002Fable to wear the watch daily for the required duration of study and to complete all required questionnaires.\n* Informed consent: understanding of the study procedures and agreement to comply with protocol.\n\nExclusion Criteria:\n\n* Recent upper respiratory infection (past 4 weeks).\n* History of hemoptysis (coughing up blood) since onset of the current cough.\n* Current smoker (incl. vaping) of any substance.\n* ≥10 consecutive pack-years smoking history within \\\u003C10 years prior to screening.\n* Diagnosed with a chronic lung condition (COPD, emphysema, lung cancer, IPF, chronic bronchitis, asthma). Note: Suspected asthma without confirmed diagnosis or benefit from asthma therapy is not an exclusion.\n* Current or past head\u002Fneck cancer.\n* Difficulty swallowing.\n* On ACE inhibitors, such as Benzapril (Lotensin), Captopril (Capoten), Enalapril\u002FEnalaprilat (Vasotec oral and injectable), Fosinopril (Monopril), Lisinopril (Zestril and Prinivil), Moexipril (Univasc), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), and Trandolapril (Mavik)\n* Prior treatment for cough by a speech-language pathologist.\n* Living with another individual with a frequent cough that would interfere with monitoring.\n* Participation in any cough intervention study within 30 days or 5 half-lives of the intervention.\n* Major scheduled surgery during the study period.","21 Years",{"count":197,"type":21},20,[199],"NA","The goal of this single-cohort clinical trial is to learn whether a smartphone-based Cough Management (CM) program can reduce cough frequency and burden in adults (21-80 years) who have refractory or unexplained chronic cough. \n\nThe main questions it aims to answer are:\n\n* Does four weeks of using the CM feature in the CoughPro app lower objective cough rate (coughs per hour) compared with each participant's one-week baseline? \n* Does the program also lessen cough intensity (bout metrics) and improve patient-reported quality-of-life scores on the Leicester Cough Questionnaire and PGI-S?\n\nParticipants will:\n\n* Wear a Hyfe CoughMonitor smartwatch continuously for 6 weeks (1-week baseline, 4-week intervention, 1-week follow-up), charging it nightly. \n* Complete science-based in-app CM lessons based on behavioral cough-suppression therapy and practice the techniques during the 4-week intervention.\n* Fill out online questionnaires (LCQ and PGI-S) at baseline and at the end of Week 4.\n* Join a brief exit interview, then return the smartwatch and receive a compensation voucher.",[27,83,202],"Cough Hypersensitivity",[90,204,205,206,88,89,207,208,209,210,211,212,213,214,215,216,217,218,144,219,220,221],"hyfe","cough monitoring","coughpro","digital therapeutic","DTx","software enhanced treatment","cough management","behavioural cough suppression techniques","BCST","digital health","CoughMonitor Suite","cough tracking","cough recording","cough bouts","coughing","urge to cough","cough-free time","Leicester Cough Questionnaire (LCQ)","2025-09-10",{"date":224,"type":32},"2025-09-11",{"date":226,"type":32},"2025-03-27",{"date":228,"type":21},"2025-09",{"name":230,"class":101},"Hyfe Inc",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":158},"100570401","early-phase-1-group-telehealth-behavioral-cough-suppression-therapy-100570401","NCT06706765","Group Telehealth Behavioral Cough Suppression Therapy","Group Telehealth Behavioral Cough Suppression Therapy Pilot Study","Inclusion Criteria:\n\n* At least 18 years old\n* Predominantly dry cough for at least 8 weeks\n* Evaluated and treated by at least one physician for cough\n* Obtained a chest X-ray or chest CT scan specifically related to the cough with unremarkable results\n* Access to a computer or tablet that includes a camera and able to use the device independently\n* Reliable internet access\n* Willing to agree to maintain confidentiality of personal information (including names) related to others in the study\n\nExclusion Criteria:\n\n* Under age 18\n* Coughing up blood\n* Current smoker of any substance\n* History of smoking or 10 or more years\n* Diagnosed with a chronic lung condition (e.g., COPD, emphysema, lung cancer, idiopathic pulmonary fibrosis, chronic bronchitis, asthma)? (NOTE: If a patient has been told their cough may be (or is likely) due to asthma but they have not had any formal lung testing and asthma treatments have not helped your cough, we don't consider this a formal asthma diagnosis and will not exclude them from the study.)\n* Diagnosed currently or in the past with head and neck cancer (i.e., cancer of the mouth, nose, or throat).\n* Complaints of swallowing difficulty\n* Taking any of the following medications, which have a known side effect of cough: Benzapril (Lotensin), Captopril (Capoten), Enalapril\u002FEnalaprilat (Vasotec oral and injectable), Fosinopril (Monopril), Lisinopril (Zestril and Prinivil), Moexipril (Univasc), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), and Trandolapril (Mavik)\n* Prior BCST treatment with an SLP or respiratory therapist",{"count":239,"type":21},60,[241],"EARLY_PHASE1","The purpose of this study is to investigate the effectiveness of behavioral cough suppression therapy (BCST) in managing refractory chronic cough (RCC) within a group telehealth setting. RCC is a cough that has lasted at least 8 weeks and has not resolved with standard medical treatment. BCST is a research-based treatment provided by specialty-trained speech-language pathologists (SLPs) for patients with RCC. Although the treatment works very well for a large proportion of patients in a standard one-on-one format, there are a limited number of SLPs available to provide this treatment and patients living in rural areas do not typically have access to an SLP trained in BCST. If BCST can effectively be delivered in a group telehealth model, it would significantly improve accessibility to the treatment.",[27],"2024-11-25",{"date":246,"type":32},"2024-11-27",{"date":248,"type":32},"2024-03-22",{"date":250,"type":21},"2025-01-31",{"name":100,"class":101}]